Veenat contains Imatinib 400 mg, a targeted therapy used to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It works by blocking proteins that promote cancer cell growth.
| Generic Name | Imatinib 400 mg |
| Manufacturer | Natco |
| Packing | 30 Tablets |
| Prescribed For | Chronic Myeloid Leukemia and Gastrointestinal Stromal tumors |
| Expiry | December 2027 |
Soranib contains Sorafenib 200 mg, a targeted therapy used for liver, kidney, and thyroid cancers. It works by blocking proteins that help cancer cells grow and spread.
| Generic Name | Sorafenib |
| Manufacturer | CIPLA |
| Packing | 120 Tablets |
| Prescribed For | Liver cancer, kidney cancer, and thyroid cancer |
| Expiry | December 2027 |
Sorafenat contains Sorafenib 200 mg, a targeted cancer therapy used for liver cancer, kidney cancer, and thyroid cancer. It works by blocking signals that promote tumor growth and spread.
| Generic Name | Sorafenib |
| Manufacturer | NATCO |
| Packing | 120 Tablets |
| Prescribed For | Liver cancer, kidney cancer, and thyroid cancer |
| Expiry | December 2027 |
Resihance contains Regorafenib 40 mg, a targeted therapy used to treat metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and liver cancer. It works by blocking proteins that help cancer cells grow and spread.
| Generic Name | Regorafenib |
| Manufacturer | Bayer Zydus Pharma |
| Packing | 28 Tablets |
| Prescribed For | Metastatic colorectal cancer, gastrointestinal stromal tumors, and liver cancer |
| Expiry | December 2027 |
Nublexa contains Regorafenib 40 mg, a targeted cancer therapy used for treating metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma. It works by blocking proteins that promote tumor growth.
| Generic Name | Regorafenib |
| Manufacturer | Bayer Zydus Pharma |
| Packing | 28 Tablets |
| Prescribed For | Metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma |
| Expiry | December 2027 |
Kryxana contains Ribociclib 200mg, a targeted cancer therapy used for treating HR-positive, HER2-negative advanced or metastatic breast cancer. It works by slowing the growth and spread of cancer cells.
| Generic Name | Ribociclib |
| Manufacturer | NOVARTIS |
| Packing | 21 Tablets |
| Prescribed For | Metastatic breast cancer |
| Expiry | December 2027 |
Erlonat is a targeted cancer therapy used for treating non-small cell lung cancer and pancreatic cancer. It works by blocking signals that help cancer cells grow and spread.
| Generic Name | Erlotinib |
| Manufacturer | Natco |
| Packing | 30 Tablets |
| Prescribed For | Lung and Pancreatic Cancers |
| Expiry | December 2027 |
Erlocip contains Erlotinib 100 mg, a targeted therapy used in the treatment of certain types of lung and pancreatic cancers. It works by blocking cancer cell growth.
| Generic Name | Erlotinib |
| Manufacturer | CIPLA |
| Packing | 30 Tablets |
| Prescribed For | Lung and Pancreatic Cancers |
| Expiry | December 2027 |
Cetuxa contains Cetuximab, a monoclonal antibody used to treat certain types of colorectal cancer and head & neck cancers. It works by targeting the EGFR protein on cancer cells, helping to slow tumor growth.
| Composition | Cetuximab |
| Manufacturer | ALKEM LABORATORIES LTD |
| Packing | 1 Vial(s) Of 20ml |
| Prescribed For | Colorectal, head and neck cancer |
| Expiry | December 2027 |
BDPARP contains Olaparib 150 mg, a targeted therapy used to treat certain types of ovarian, breast, pancreatic, and prostate cancers. It works by blocking PARP enzymes to help stop cancer cells from repairing themselves.
| Composition | Olaparib |
| Manufacturer | BDR |
| Packing | 28 Tablets |
| Prescribed For | Ovarian, Breast, Pancreatic, Prostate cancer |
| Expiry | December 2027 |
Ribaxa contains Olaparib, a targeted PARP inhibitor used in the treatment of certain types of ovarian, breast, prostate, and pancreatic cancers. It works by blocking cancer cell repair pathways, helping slow or stop tumor growth.
| Composition | Olaparib |
| Manufacturer | Dr. Reddy’s |
| Packing | 60 Tablets |
| Prescribed For | Ovarian, Breast, Pancreatic, Prostate cancer |
| Expiry | December 2027 |
Ibyra (Olaparib 150mg Tablets) is a targeted therapy used to treat ovarian, breast, pancreatic, and prostate cancers with BRCA gene mutations. It works by blocking cancer cell repair, slowing their growth.
| Composition | Olaparib |
| Manufacturer | Zydus |
| Packing | 60 Tablets |
| Prescribed For | Ovarian, Breast, Pancreatic, Prostate cancer |
| Expiry | December 2027 |
Apaluside (Apalutamide 60mg) is an anti-androgen medicine used to treat prostate cancer, helping slow its growth and spread in advanced or metastatic stages.
| Composition | Apalutamide |
| Manufacturer | Lucien |
| Packing | 120 Tablets |
| Prescribed For | Prostate cancer |
| Expiry | December 2027 |
Tukavo (Tucatinib 150mg) is a targeted therapy used to treat HER2-positive advanced and metastatic breast cancer, usually in combination with other medicines.
| Composition | Tucatinib |
| Manufacturer | Zydus |
| Packing | 60 Tablets |
| Prescribed For | HER2-positive metastatic breast cancer |
| Expiry | December 2027 |
Tuccatinn (Tucatinib 150mg) is a targeted therapy indicated for the treatment of HER2-positive advanced and metastatic breast cancer, often prescribed along with other medications.
| Composition | Tucatinib |
| Manufacturer | BDR |
| Packing | 60 Tablets |
| Prescribed For | HER2-positive metastatic breast cancer |
| Expiry | December 2027 |
Tucanat contains Tucatinib, a targeted therapy used to treat HER2-positive breast cancer, often in combination with other medicines. It helps slow cancer growth, prevent spread, and improve survival in advanced or metastatic cases.
| Composition | Tucatinib |
| Manufacturer | Natco |
| Packing | 60 Tablets |
| Prescribed For | HER2-positive metastatic breast cancer |
| Expiry | December 2027 |
Cabozer (Cabozantinib 40mg Tablet) is used to treat advanced kidney, liver, and thyroid cancers by blocking cancer cell growth and spread.
| Composition | Cabozantinib |
| Manufacturer | Aprazer |
| Packing | 30 Tablets |
| Prescribed For | Kidney, Liver, and Thyroid Cancers |
| Expiry | December 2027 |
Acaya (Acalabrutinib 100 mg) is a targeted oral therapy used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
| Composition | Acalabrutinib |
| Manufacturer | Zydus |
| Packing | 60 Capsules |
| Prescribed For | Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma |
| Expiry | December 2027 |
Acalnib Acalabrutinib 100 mg Capsules are an oral targeted therapy used for the treatment of certain blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
| Composition | Acalabrutinib |
| Manufacturer | Hetero |
| Packing | 30 Capsules |
| Prescribed For | Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma |
| Expiry | December 2027 |
Acabrunat Acalabrutinib 100 mg Capsules are an oral targeted therapy used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
| Composition | Acalabrutinib |
| Manufacturer | Natco |
| Packing | 30 Capsules |
| Prescribed For | Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma |
| Expiry | December 2027 |
Acaone Acalabrutinib 100 mg Capsules are an oral targeted therapy used to treat chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Acalabrutinib works by blocking the Bruton’s tyrosine kinase (BTK) enzyme, which helps prevent the growth and spread of cancer cells, thereby slowing disease progression and improving treatment outcomes.
| Composition | Acalabrutinib |
| Manufacturer | MSN |
| Packing | 30 Capsules |
| Prescribed For | Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma |
| Expiry | December 2027 |
Lenced 10mg Capsule contains Lenvatinib, a targeted cancer therapy used to treat thyroid cancer, liver cancer (HCC), and kidney cancer (RCC).
| Composition | Lenvatinib |
| Manufacturer | Zydus Cadila |
| Packing | 30 Capsules |
| Prescribed For | Thyroid cancer, Liver cancer, and Kidney cancer |
| Expiry | December 2027 |
Lenalid contains Lenalidomide 25mg, a prescription medicine used to treat certain types of blood cancers, including multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma (MCL).
| Composition | Lenalidomide |
| Manufacturer | Natco Pharma Ltd |
| Packing | 30 Capsules in 1 Bottle |
| Prescribed For | Multiple myeloma |
| Expiry | December 2027 |
Lenakast (Lenalidomide 25 mg) is an oral immunomodulatory medicine used in the treatment of multiple myeloma and certain blood disorders. It helps slow cancer cell growth, supports immune response, and is commonly used as part of combination therapy under medical supervision.
| Composition | Lenalidomide |
| Manufacturer | Aprazer Healthcare Pvt Ltd |
| Packing | 30 Capsules in 1 Bottle |
| Prescribed For | Multiple myeloma |
| Expiry | December 2027 |
Bracanat is an oral anticancer medicine containing Olaparib 150 mg, used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers.
| Composition | Olaparib |
| Manufacturer | Natco Pharma Ltd |
| Packing | 30 Tablets in 1 bottle |
| Prescribed For | Ovarian and Breast Cancer |
| Expiry | December 2027 |
Olabir is an oral anticancer medication containing Olaparib 150 mg, a PARP inhibitor used to treat cancers associated with BRCA gene mutations. It is commonly prescribed for ovarian, breast, pancreatic, and prostate cancers, helping to slow cancer progression and improve survival in advanced stages.
| Composition | Olaparib |
| Manufacturer | Aprazer Healthcare Pvt Ltd |
| Packing | 30 Tablets in 1 bottle |
| Prescribed For | Ovarian and Breast Cancer |
| Expiry | December 2027 |
Hertab contains Lapatinib 250mg, a targeted cancer therapy used in the treatment of HER2-positive breast cancer. It works by blocking specific proteins (HER2 and EGFR) that promote the growth of cancer cells, thereby slowing or stopping tumor progression.
| Composition | Lapatinib |
| Manufacturer | Hetero Healthcare Limited |
| Packing | 30 Tablets |
| Prescribed For | Breast Cancers |
| Expiry | December 2027 |
Ibrunat contains Ibrutinib 140mg, a targeted cancer therapy used to treat certain blood cancers such as Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström’s Macroglobulinemia (WM).
| Composition | Ibrutinib |
| Manufacturer | Natco Pharma Ltd |
| Packing | 30 Capsules |
| Prescribed For | Blood Cancers |
| Expiry | December 2027 |
Imat contains Imatinib 400mg, a targeted chemotherapy medicine used to treat certain types of cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).
| Composition | Imatinib |
| Manufacturer | Zydus Healthcare Limited |
| Packing | 120 Tablets |
| Prescribed For | Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumors |
| Expiry | December 2027 |
Imatikast contains Imatinib 400mg, a targeted cancer therapy used to treat certain types of cancers such as Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Gastrointestinal Stromal Tumors (GISTs).
| Composition | Imatinib |
| Manufacturer | Aprazer Healthcare Pvt Ltd |
| Packing | 10 Tablets in 1 Strip |
| Prescribed For | Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Gastrointestinal Stromal Tumors |
| Expiry | December 2027 |
Indenza is an anti-cancer medication that contains Enzalutamide 40mg, used primarily in the treatment of prostate cancer.
| Composition | Enzalutamide 40mg |
| Manufacturer | Aprazer Healthcare Pvt Ltd |
| Packing | 112 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Invista contains Dasatinib 100mg, a targeted cancer medication used in the treatment of certain types of blood cancers, including Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL) that are Philadelphia chromosome-positive.
| Composition | Dasatinib |
| Manufacturer | Dr Reddy’s Laboratories Ltd |
| Packing | 30 Tablets |
| Prescribed For | Chronic Myeloid Leukemia |
| Expiry | December 2027 |
Lenangio contains Lenalidomide 25mg, a medicine used to treat certain types of blood cancers such as multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma (MCL).
| Composition | Lenalidomide |
| Manufacturer | Dr Reddy’s Laboratories Ltd |
| Packing | 10 Capsules |
| Prescribed For | Multiple Myeloma, Myelodysplastic Syndrome and Mantle Cell Lymphoma |
| Expiry | December 2027 |
Lenshil contains Lenvatinib 4mg, a targeted cancer medicine used in the treatment of thyroid cancer, kidney cancer (renal cell carcinoma), and liver cancer (hepatocellular carcinoma).
| Composition | Lenvatinib |
| Manufacturer | Shilpa Medicare Ltd |
| Packing | 10 Capsules |
| Prescribed For | Thyroid Cancer, Kidney Cancer, Liver Cancer |
| Expiry | December 2027 |
Lentris contains Lenvatinib 10mg, a targeted cancer therapy used to treat advanced stages of thyroid cancer, liver cancer (hepatocellular carcinoma), and kidney cancer (renal cell carcinoma).
| Composition | Lenvatinib |
| Manufacturer | Mylan Pharmaceuticals Pvt Ltd |
| Packing | 30 Capsules |
| Prescribed For | Thyroid Cancer, Kidney Cancer, Liver Cancer |
| Expiry | December 2027 |
Lenvakast contains Lenvatinib 10mg, a targeted therapy used in the treatment of advanced thyroid cancer, renal cell carcinoma (kidney cancer), and hepatocellular carcinoma (liver cancer).
| Composition | Lenvatinib |
| Manufacturer | Aprazer Healthcare Pvt Ltd |
| Packing | 30 Capsules |
| Prescribed For | Thyroid Cancer, Kidney Cancer, Liver Cancer |
| Expiry | December 2027 |
Lenvat contains Lenvatinib 10mg, a targeted therapy used in the treatment of thyroid cancer, kidney cancer (renal cell carcinoma), and liver cancer (hepatocellular carcinoma).
| Composition | Lenvatinib |
| Manufacturer | Natco Pharma Ltd |
| Packing | 30 Capsules |
| Prescribed For | Thyroid Cancer, Kidney Cancer, Liver Cancer |
| Expiry | December 2027 |
Lenvatol contains Lenvatinib 10mg, a targeted anti-cancer medicine used for treating certain types of advanced or metastatic cancers including thyroid cancer, renal cell carcinoma (kidney cancer), and hepatocellular carcinoma (liver cancer).
| Composition | Lenvatinib |
| Manufacturer | Cipla Ltd |
| Packing | 10 Capsules |
| Prescribed For | Thyroid Cancer, Kidney Cancer, Liver Cancer |
| Expiry | December 2027 |
Lenvenib contains Lenvatinib 4mg, a targeted cancer therapy used to treat advanced thyroid cancer, kidney cancer (renal cell carcinoma), and liver cancer (hepatocellular carcinoma).
| Composition | Lenvatinib |
| Manufacturer | Sun Pharmaceutical Industries Ltd |
| Packing | 7 Capsules in 1 Strip |
| Prescribed For | Thyroid Cancer, Kidney Cancer, Liver Cancer |
| Expiry | December 2027 |
Leu Kinib contains Dasatinib 70mg, a targeted therapy used for treating certain types of blood cancers such as Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Sayre Therapeutics Pvt Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Mitomycin Injection 40mg is an anti-cancer (chemotherapy) medication used to treat various types of cancers, including stomach cancer, pancreatic cancer, breast cancer, bladder cancer, and others.
| Manufacturer | Biochem Pharmaceutical Industries |
| Packing | 1.0 Injection in 1 vial |
| Prescribed For | Stomach Cancer, Pancreatic Cancer, Breast Cancer and Bladder Cancer |
| Expiry | December 2027 |
Nextki contains Dasatinib 100mg, a targeted cancer therapy used to treat certain blood cancers, specifically Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Emcure Pharmaceuticals Ltd |
| Packing | 30 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Nitib contains Ibrutinib 140mg, a targeted therapy used to treat certain types of blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia.
| Composition | Ibrutinib |
| Manufacturer | Hetero Healthcare Limited |
| Packing | 30 Capsules |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Nitnib contains Sunitinib 50mg Malate, a targeted cancer therapy used to treat certain types of cancers including advanced renal cell carcinoma (kidney cancer), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET).
| Composition | Sunitinib |
| Manufacturer | Zydus Cadila |
| Packing | 7 Capsules |
| Prescribed For | Kidney Cancer, Gastrointestinal Stromal Tumors & Pancreatic Neuroendocrine Tumors |
| Expiry | December 2027 |
Nuparp contains Rucaparib 300mg, a PARP (poly ADP-ribose polymerase) inhibitor used in the treatment of certain types of cancer, including advanced ovarian and prostate cancers associated with BRCA mutations.
| Composition | Rucaparib |
| Manufacturer | Zydus Cadila |
| Packing | 60 Tablets in a Bottle |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Obnyx contains Enzalutamide 40mg, an oral anti-cancer medication used to treat metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC) in adult men.
| Generic Name | Enzalutamide |
| Manufacturer | Zydus Cadila |
| Packing | 28 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Pazinib contains Pazopanib 400mg, and is used to treat advanced kidney cancer (renal cell carcinoma) and certain types of soft tissue sarcoma in adults who have received prior chemotherapy.
| Composition | Pazopanib |
| Manufacturer | Hetero Healthcare Limited |
| Packing | 30 Tablets in 1 Bottle |
| Prescribed For | Kidney Cancer |
| Expiry | December 2027 |
Pemetero 500 mg Injection contains Pemetrexed, an anti-cancer medication used primarily to treat non-small cell lung cancer(NSCLC) and malignant pleural mesothelioma.
| Composition | Pemetrexed |
| Manufacturer | Hetero Healthcare Limited |
| Packing | 1 Injection in 1 Vial |
| Prescribed For | Lung Cancer |
| Expiry | December 2027 |
Piclib contains Palbociclib 125 mg, a targeted therapy used in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer.
| Composition | Palbociclib |
| Manufacturer | Hetero Healthcare Limited |
| Packing | 21 Capsules in 1 Bottle |
| Prescribed For | Metastatic Breast Cancer |
| Expiry | December 2027 |
Pomalid contains Pomalidomide 2mg, an immunomodulatory drug used in the treatment of multiple myeloma (a type of blood cancer), especially in patients who have not responded to other therapies such as lenalidomide and bortezomib.
| Composition | Pomalidomide |
| Manufacturer | Natco Pharma Ltd |
| Packing | 21 Capsules in 1 Bottle |
| Prescribed For | Multiple Myeloma |
| Expiry | December 2027 |
Ramiven contains Abemaciclib 150mg, a cancer medicine used in the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
| Composition | Abemaciclib 150mg |
| Manufacturer | Eli Lilly and Company India Pvt Ltd |
| Packing | 14 Tablets |
| Prescribed For | Metastatic Breast Cancer |
| Expiry | December 2027 |
Regonat contains Regorafenib 40 mg, a targeted chemotherapy medicine used to treat certain types of cancers, including colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (liver cancer).
| Composition | Regorafenib |
| Manufacturer | Natco Pharma Ltd |
| Packing | 28 Tablets |
| Prescribed For | Colorectal Cancer, Liver Cancer and GIST |
| Expiry | December 2027 |
Sorafekast 200mg contains Sorafenib, a targeted cancer therapy used in the treatment of advanced liver cancer (Hepatocellular Carcinoma), kidney cancer (Renal Cell Carcinoma), and certain types of thyroid cancer.
| Composition | Sorafenib (200mg) |
| Manufacturer | Aprazer Healthcare Pvt Ltd |
| Packing | 30 Tablets in 1 Bottle |
| Prescribed For | Liver Cancer, Kidney Cancer and Thyroid Cancer |
| Expiry | December 2027 |
Spnib 50mg/100mg contains dasatinib, a tyrosine kinase inhibitor used to treat certain types of blood cancers, specifically chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+).
| Composition | Dasatinib |
| Manufacturer | Zydus Cadila |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Sprycel 50mg contains Dasatinib, a targeted cancer therapy used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | BMS India Pvt Ltd |
| Packing | 60 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Stivarga 40 mg Tablet contains Regorafenib, an oral targeted therapy used to treat certain types of cancers such as metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (liver cancer).
| Composition | Regorafenib |
| Manufacturer | Bayer |
| Packing | 28 Tablets in 1 Bottle |
| Prescribed For | Metastatic Colorectal Cancer, GIST, and Hepatocellular Carcinoma |
| Expiry | December 2027 |
Sunicine 50mg Capsule contains Sunitinib, a targeted cancer therapy used to treat various cancers, including advanced kidney cancer (Renal Cell Carcinoma), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET).
| Composition | Sunitinib |
| Manufacturer | Arechar Healthcare |
| Packing | 28 Capsules in 1 Bottle |
| Prescribed For | Kidney Cancer and GIST, pNET |
| Expiry | December 2027 |
Sunisam 50 mg Capsules contains Sunitinib, an oral targeted therapy used in the treatment of various cancers, including advanced kidney cancer (Renal Cell Carcinoma), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET).
| Composition | Sunitinib |
| Manufacturer | Samarth Life Sciences Pvt Ltd |
| Packing | 28 Capsules |
| Prescribed For | Kidney Cancer, GIST and pNET |
| Expiry | December 2027 |
Sunitax 25 mg capsule is a targeted cancer therapy containing Sunitinib Malate, used primarily to treat certain types of advanced cancers such as renal cell carcinoma (kidney cancer) and gastrointestinal stromal tumors (GIST).
| Composition | Sunitinib |
| Manufacturer | Aureate Healthcare Pvt Ltd |
| Packing | 7 Capsules in 1 Strip |
| Prescribed For | Kidney Cancer and Gastrointestinal Stromal Tumors |
| Expiry | December 2027 |
Sunixar 25/50mg Capsule is an oral cancer medication containing Sunitinib Malate, used to treat advanced kidney cancer (renal cell carcinoma), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors.
| Composition | Sunitinib |
| Manufacturer | Sun Pharmaceutical Industries Ltd |
| Packing | 7 capsules in 1 Strip |
| Prescribed For | Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumors |
| Expiry | December 2027 |
Sutekast 50 mg Capsule is an oral cancer medication containing Sunitinib Malate, used in the treatment of advanced cancers such as renal cell carcinoma (kidney cancer), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors.
| Composition | Sunitinib |
| Manufacturer | Aprazer Healthcare Pvt Ltd |
| Packing | 28 Capsules in 1 Bottle |
| Prescribed For | Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumors |
| Expiry | December 2027 |
Sutib 50mg Capsule contains Sunitinib Malate, a targeted cancer treatment used for managing advanced cancers such as renal cell carcinoma (kidney cancer), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors.
| Composition | Sunitinib |
| Manufacturer | Glenmark Pharmaceuticals Ltd |
| Packing | 28 Capsules |
| Prescribed For | Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumors |
| Expiry | December 2027 |
Sutinat 50mg Capsule is an oral anti-cancer medication that contains Sunitinib Malate, a targeted therapy used to treat certain advanced cancers such as renal cell carcinoma (kidney cancer), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors.
| Composition | Sunitinib |
| Manufacturer | Natco Pharma Ltd |
| Packing | 28 Capsules in 1 Bottle |
| Prescribed For | Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumors |
| Expiry | December 2027 |
Sutykine 50 mg Capsule is an oral targeted therapy that contains Sunitinib Malate, used in the treatment of advanced cancers such as renal cell carcinoma (kidney cancer), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors.
| Composition | Sunitinib |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Packing | 70 Capsules |
| Prescribed For | Anticancer |
| Expiry | December 2027 |
Svitinib 50mg Capsule is an oral anti-cancer medication containing Sunitinib Malate, a targeted therapy used in the treatment of renal cell carcinoma (kidney cancer), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors.
| Composition | Sunitinib |
| Packing | 30 Capsules |
| Prescribed For | Kidney Cancer, GIST and Pancreatic Neuroendocrine Tumors |
| Expiry | December 2027 |
Tipanat 20 is an oral chemotherapy medication used in the treatment of advanced or metastatic colorectal cancer and gastric (stomach) cancer. It contains a combination of Trifluridine (antineoplastic agent) and Tipiracil (a thymidine phosphorylase inhibitor).
| Composition | Tipiracil (8.19mg) + Trifluridine (20mg) |
| Manufacturer | Natco Pharma Ltd |
| Packing | 20 Tablets in 1 Bottle |
| Prescribed For | Stomach Cancer |
| Expiry | December 2027 |
Tunib 50mg Capsule contains Sunitinib Malate, a targeted cancer therapy used to treat advanced renal cell carcinoma (kidney cancer), gastrointestinal stromal tumors (GIST), and certain types of pancreatic neuroendocrine tumors.
| Composition | Sunitinib |
| Manufacturer | Mankind Pharmaceuticals Limited |
| Packing | 28 Capsules in 1 Bottle |
| Prescribed For | Kidney Cancer |
| Expiry | December 2027 |
Xbira 250 mg and 500 mg tablets contain Abiraterone Acetate, a hormonal therapy used in the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC).
| Composition | Abiraterone Acetate |
| Manufacturer | Cipla Ltd |
| Packing | 120 Tablets in a Bottle |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Xylutide 40mg Capsule contains Enzalutamide, a medication used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer.
| Composition | Enzalutamide |
| Manufacturer | Cipla Ltd |
| Packing | 28 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Zecyte 250mg Tablet contains Abiraterone Acetate, a hormonal therapy used to treat metastatic castration-resistant prostate cancer (mCRPC).
| Composition | Abiraterone Acetate |
| Manufacturer | Cipla Ltd |
| Packing | 120 Tablets in a Bottle |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Zoldonat 4 mg Injection contains zoledronic acid and is used to treat high blood calcium levels caused by cancer, prevent bone complications in cancers like breast or prostate cancer, and manage conditions such as osteoporosis and Paget’s disease.
| Composition | Zoledronic Acid |
| Manufacturer | Natco Pharma Ltd |
| Packing | 1 Injection in 1 vial |
| Prescribed For | Osteoporosis |
| Expiry | December 2027 |
Glenza 40 mg capsule has enzalutamide in it and is used to treat advanced prostate cancer, particularly in men whose cancer does not respond to hormone therapy, regardless of whether it has spread to other parts of the body.
| Composition | Enzalutamide |
| Manufacturer | Glenmark Pharmaceuticals Ltd |
| Packing | 28 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Glenvas 10mg Capsule contains Lenvatinib, an oral targeted therapy used to treat certain types of advanced cancers, including thyroid cancer, liver cancer, kidney cancer, and endometrial cancer.
| Composition | Lenvatinib |
| Manufacturer | Glenmark Pharmaceuticals Ltd |
| Packing | 30 Capsules |
| Prescribed For | Thyroid, Liver & Kidney Cancer |
| Expiry | December 2027 |
Evermil 5mg tablet contains Everolimus, an anti-cancer medicine used to treat certain types of advanced kidney cancer, breast cancer, neuroendocrine tumors, and tuberous sclerosis-related conditions.
| Composition | Everolimus |
| Manufacturer | Glenmark Pharmaceuticals Ltd |
| Packing | 10 Tablets in 1 Strip |
| Prescribed For | Neuroendocrine Tumors, Kidney & Breast Cancer |
| Expiry | December 2027 |
Enzyl 40mg capsule is an oral anti-cancer medication containing Enzalutamide, primarily used to treat advanced prostate cancer, especially castration-resistant prostate cancer (CRPC).
| Composition | Enzalutamide |
| Manufacturer | Sun Pharmaceutical Industries Ltd |
| Packing | 112 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Enzana 40mg Capsule contains Enzalutamide, a medication used to treat prostate cancer that has spread or is resistant to standard hormone therapy.
| Composition | Enzalutamide |
| Manufacturer | Hetero Healthcare Limited |
| Packing | 56 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Enzamide 40 mg contains enzalutamide, a nonsteroidal androgen receptor inhibitor prescribed primarily for castration-resistant prostate cancer (CRPC)—both metastatic (spread beyond the prostate) and non-metastatic forms.
| Composition | Enzalutamide |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Packing | 56 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Dyronib 50 mg Tablet is an oral anti-cancer medication containing Dasatinib, a tyrosine kinase inhibitor used in the treatment of Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) and acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Hetero Healthcare Limited |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Daslemia 70 mg is an oral prescription medication that contains dasatinib, a targeted therapy classified as a tyrosine kinase inhibitor (TKI), and it is primarily used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Ph+ acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Intas Pharmaceuticals Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasatrue 70 mg tablet contains dasatinib and is used to treat certain types of blood cancer, especially chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It helps stop the growth of abnormal white blood cells.
| Composition | Dasatinib |
| Manufacturer | Cipla Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasashil 70mg is a prescription cancer medicine that contains Dasatinib, a tyrosine kinase inhibitor (TKI), and it is primarily used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Shilpa Medicare Ltd |
| Packing | 60 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasapan 70mg is a prescription medicine that contains Dasatinib, a potent tyrosine kinase inhibitor (TKI) used in the treatment of specific blood cancers. It is primarily prescribed to patients with Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Mankind Pharma Ltd |
| Packing | 60 Tablets in 1 Bottle |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Dasamyl 100 mg contains dasatinib, and it is a targeted therapy medication used in the treatment of certain types of blood cancer, specifically Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
| Composition | Dasatinib |
| Manufacturer | Mylan Pharmaceuticals Pvt Ltd |
| Packing | 30 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
| Composition | Dasatinib |
| Manufacturer | AMPS Biotech Pvt Ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
| Composition | Dasatinib |
| Manufacturer | Aprazer Healthcare Pvt ltd |
| Packing | 60 Tablets |
| Prescribed For | Blood Cancer |
| Expiry | December 2027 |
Cycokast 50mg Injection contains Cisplatin, a platinum-based chemotherapy drug used to treat various types of cancer, including bladder, ovarian, testicular, lung, and cervical cancers.
| Composition | Cisplatin |
| Manufacturer | Aprazer Healthcare Pvt ltd |
| Packing | 1 Vial |
| Prescribed For | Anti-cancer |
| Expiry | December 2027 |
Crizalk 250mg Capsule contains Crizotinib, a targeted cancer therapy used to treat patients with non-small cell lung cancer (NSCLC) that is positive for ALK (anaplastic lymphoma kinase) or ROS1 gene rearrangements.
| Composition | Crizotinib |
| Manufacturer | Pfizer Ltd |
| Packing | 60 Capsules |
| Prescribed For | Lung Cancer |
| Expiry | December 2027 |
Cazanat 60mg contains Cabozantinib, a targeted therapy used in the treatment of certain types of cancers, including advanced kidney cancer (renal cell carcinoma) and liver cancer (hepatocellular carcinoma).
| Composition | Cabozantinib |
| Manufacturer | Natco Pharma Ltd |
| Packing | 30 Tablets |
| Prescribed For | Kidney and Liver Cancer |
| Expiry | December 2027 |
Carbotero 450mg contains Carboplatin, a platinum-based chemotherapy drug. It is used to treat various types of cancer by damaging the DNA of cancer cells, preventing them from growing and dividing.
| Composition | Carboplatin |
| Manufacturer | Hetero Drugs Ltd |
| Packing | 1 vial(s) of 45 ml |
| Prescribed For | Anticancer |
| Expiry | December 2027 |
Capnat 500mg tablet contains Capecitabine, a chemotherapy medicine used to treat several cancers, including breast cancer, colon cancer, and rectal cancer.
| Composition | Capecitabine |
| Manufacturer | Natco Pharma Ltd |
| Packing | 100 Tablets |
| Prescribed For | Breast, Colon, Rectal Cancer |
| Expiry | December 2027 |
Bevatas 400mg injection contains Bevacizumab, a monoclonal antibody used in the treatment of various types of cancers, including colorectal cancer, lung cancer, kidney cancer, ovarian cancer, and glioblastoma.
| Composition | Bevacizumab |
| Manufacturer | Intas Pharmaceuticals |
| Packing | 16.0 ml in 1 bottle |
| Prescribed For | Anti Cancer |
| Expiry | December 2027 |
Bdron 500mg Tablet contains Abiraterone Acetate, a hormonal therapy used in the treatment of advanced prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC).
| Composition | Abiraterone Acetate |
| Manufacturer | BDR Pharmaceuticals |
| Packing | 60 Tablets |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Bdrelin 3.75mg Injection contains Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist used to treat hormone-sensitive conditions such as advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.
| Composition | Triptorelin |
| Manufacturer | BDR Pharmaceuticals |
| Packing | 1 Vial |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Bdfoie 10 mg Capsule contains Lenvatinib, a targeted therapy used in the treatment of certain types of cancers including thyroid cancer, advanced renal cell carcinoma (kidney cancer), and hepatocellular carcinoma (liver cancer).
| Composition | Lenvatinib |
| Manufacturer | BDR Pharmaceuticals |
| Packing | 30 Capsules |
| Prescribed For | Thyroid, Kidney, Lung Cancer |
| Expiry | December 2027 |
Bdenza 40mg Capsule contains Enzalutamide, a potent anti-androgen medication used in the treatment of advanced prostate cancer
| Composition | Enzalutamide |
| Manufacturer | Prakash Biopharma |
| Packing | 112 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Azel 40mg Capsule is a prescription medicine that contains enzalutamide, a powerful androgen receptor inhibitor, and it is mainly prescribed for the treatment of advanced prostate cancer.
| Composition | Enzalutamide |
| Manufacturer | Dr Reddy’s Laboratories Ltd |
| Packing | 112 Capsules |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Apnat 60mg Tablet contains Apalutamide, an anti-androgen medication used in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).
| Composition | Apalutamide |
| Manufacturer | Natco Pharma Ltd |
| Packing | 120 Tablets |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Ahabir 500mg Tablet contains Abiraterone Acetate, a hormonal therapy used in the treatment of metastatic castration-resistant prostate cancer (mCRPC).
| Composition | Abiraterone Acetate |
| Manufacturer | Hetero Drugs Ltd |
| Packing | 60 Tablets |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
Afanat 40mg contains Afatinib, a targeted cancer therapy used to treat non-small cell lung cancer (NSCLC) that is EGFR mutation-positive.
| Composition | Afatinib |
| Manufacturer | Natco Pharma Ltd |
| Packing | 28 Tablets |
| Prescribed For | Lung Cancer |
| Expiry | December 2027 |
Abirakast 250mg Tablet contains Abiraterone Acetate and is primarily used in the treatment of advanced prostate cancer.
| Composition | Abiraterone Acetate (250mg) |
| Manufacturer | Aprazer Healthcare Pvt. Ltd. |
| Packing | 120 tablets in 1 bottle |
| Prescribed For | Prostate Cancer |
| Expiry | December 2027 |
